
Sodium-glucose cotransporter-2 (SGLT2) inhibitors significantly reduced hospitalization for heart failure, cardiovascular death, all-cause mortality, recurrent myocardial infarction, arrhythmias, and renal injury in post-MI patients. They also improved left ventricular ejection fraction and end-diastolic volume.
Like
Save
Share